Coherus is a leading global biosimilar company. We are committed to improving patient lives by expanding access to life-changing biologic medicines.
Location: United States, California, Camarillo
Employees: 201-500
Total raised: $105M
Founded date: 2010
Investors 5
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | Kohlberg K... | kkr.com |
| - | Eight Road... | eightroads... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.02.2021 | - | $50M | - |
| 19.05.2014 | Series C | $55M | - |
Mentions in press and media 14
| Date | Title | Description |
| 15.07.2024 | HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer | ROCKVILLE, Md. and SEOUL, South Korea, July 15, 2024 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Christopher W. Slavinsky as Chief Business Development and Legal Officer. HanAll Biopharma Appoints Ch... |
| 27.06.2024 | Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction | REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash... |
| 13.03.2024 | Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update | - |
| 13.03.2024 | Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update | – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net sales of $52.4 million in the fourth quarter and... |
| 05.03.2024 | Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 | - |
| 22.01.2024 | Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal | - |
| 17.11.2021 | Deloitte Fast 500: Medical device company takes the top spot but software continues to dominate the top 10 | For the 26th straight year, software companies continued to dominate the Deloitte Technology Fast 500, but biotech and medical device companies also captured top spots. Axonics (Nasdaq: AXNX), a medical technology company, topped the 2021 l... |
| 02.02.2021 | Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences | - |
| 29.12.2019 | FDA to decide on Spectrum Pharmaceuticals’ neutropenia drug by Oct. 2020 | In a note to investors, B. Riley FBR analyst Mayank Mamtani wrote that the drug would see a likely approval and launch around the fourth quarter of next year, with an entry into the G-CSF market – valued at $3 billion or more – in 2021. The... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
Show more